MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
BioSig Technologies Accounts Receivables 2011-2026 | BSGM
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables BioSig Technologies
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 109 K | 24 K | 9 K | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 109 K | 9 K | 47.3 K |
Quarterly Accounts Receivables BioSig Technologies
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 109 K | 109 K | 81 K | 54 K | 14 K | 24 K | 14 K | 21 K | 17 K | 9 K | 5 K | - | - | - | 100 K | 199 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 199 K | 5 K | 58.2 K |
Accounts Receivables of other stocks in the Medical devices industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acutus Medical
AFIB
|
11.4 M | - | -26.83 % | $ 2.62 M |  USA |
 |
Allied Healthcare Products
AHPI
|
2.37 M | - | 3.58 % | $ 2.21 M | USA |
 |
Alphatec Holdings
ATEC
|
97.3 M | $ 12.42 | -4.46 % | $ 1.86 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
44.8 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
3.26 M | - | 1.37 % | $ 20.5 M | USA |
 |
Bruker Corporation
BRKR
|
566 M | $ 38.55 | 0.13 % | $ 5.74 K | USA |
 |
Cognyte Software Ltd.
CGNT
|
175 M | $ 8.31 | 1.4 % | $ 597 M |  Israel |
 |
Conformis
CFMS
|
9.77 M | - | - | $ 16.4 M | USA |
 |
Cutera
CUTR
|
43.1 M | - | -10.19 % | $ 1.99 M | USA |
 |
AdaptHealth Corp.
AHCO
|
371 M | $ 9.61 | -0.62 % | $ 1.3 B | USA |
 |
Apollo Endosurgery
APEN
|
15 M | - | - | $ 475 M | USA |
 |
Dynatronics Corporation
DYNT
|
2.8 M | - | 14.99 % | $ 929 K | USA |
 |
Electromed
ELMD
|
24.7 M | $ 24.26 | -0.12 % | $ 205 M | USA |
 |
Cardiovascular Systems
CSII
|
39.7 M | - | 0.15 % | $ 844 M | USA |
 |
CONMED Corporation
CNMD
|
248 M | $ 41.66 | -3.09 % | $ 1.29 B | USA |
 |
EDAP TMS S.A.
EDAP
|
18.6 M | $ 4.19 | -1.41 % | $ 156 M |  France |
 |
Avinger
AVGR
|
1.01 M | - | -20.74 % | $ 369 K | USA |
 |
AxoGen
AXGN
|
26.2 M | $ 29.15 | -0.24 % | $ 1.34 B | USA |
 |
Apyx Medical Corporation
APYX
|
14 M | $ 3.27 | -0.82 % | $ 113 M | USA |
 |
Eargo
EAR
|
1.91 M | - | - | $ 10.2 M | USA |
 |
Second Sight Medical Products
EYES
|
455 K | - | -0.97 % | $ 54.4 M | USA |
 |
Accuray Incorporated
ARAY
|
83.2 M | $ 0.5 | -4.78 % | $ 51.4 M | USA |
 |
Cytosorbents Corporation
CTSO
|
7.32 M | $ 0.81 | 1.91 % | $ 44.1 M | USA |
 |
Align Technology
ALGN
|
996 M | $ 175.78 | -3.51 % | $ 13.2 B | USA |
 |
Butterfly Network
BFLY
|
20.8 M | $ 3.7 | -8.31 % | $ 783 M | USA |
 |
BIOLASE
BIOL
|
5.48 M | - | -13.19 % | $ 166 K | USA |
 |
Abbott Laboratories
ABT
|
7.93 B | $ 110.91 | -1.94 % | $ 193 B | USA |
 |
InMode Ltd.
INMD
|
10.5 M | $ 13.49 | -0.55 % | $ 872 M | Israel |
 |
IRIDEX Corporation
IRIX
|
6.73 M | $ 1.4 | -0.71 % | $ 22.6 M | USA |
 |
IRadimed Corporation
IRMD
|
10.6 M | $ 100.27 | -4.6 % | $ 1.27 B | USA |
 |
Helius Medical Technologies
HSDT
|
117 K | $ 2.26 | -2.16 % | $ 1.37 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
53.8 M | $ 17.55 | -5.03 % | $ 412 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
660 M | $ 83.7 | -1.78 % | $ 48.9 B | USA |
 |
Pulmonx Corporation
LUNG
|
13.1 M | $ 1.61 | 12.07 % | $ 63 M | USA |
 |
Inogen
INGN
|
38.9 M | $ 6.53 | 3.41 % | $ 174 M | USA |
 |
LivaNova PLC
LIVN
|
216 M | $ 64.29 | -1.49 % | $ 3.51 B |  Britain |